Vaccine Delivery (Influenza)

Companies Sign Agreement To Develop Novel Nasally Delivered Vaccines

Published in Vaccine Weekly, May 26th, 1997

BioChem Pharma Inc., Laval, Quebec, Canada, announced that its vaccines subsidiary, IAF BioVac Inc., has concluded a strategic agreement with Biovector Therapeutics SA, a privately owned French company specializing in drug and vaccine delivery technologies.

The alliance is aimed at developing novel human vaccines for nasal administration thus combining BioVac's expertise in vaccines with Biovector's innovative supra molecular biovector technology currently in development.

Under this agreement, IAF BioVac and Biovector will develop nasal vaccines for prophylactic use in at least three areas: influenza, meningococcal meningitis, and pneumococcal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry